Literature DB >> 8199566

Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group.

S R McCann1, A Bacigalupo, E Gluckman, W Hinterberger, J Hows, P Ljungman, P Marin, C Nissen, E van't Veer Kerthof, A Raghavachar.   

Abstract

Six hundred and eighteen patients with acquired aplastic anaemia grafted from an HLA-identical sibling donor between 1976 and 1990 in eight European centres were reported to the Working Party for Severe Aplastic Anaemia (SAA) Registry and were evaluable for analysis of the incidence of graft failure/rejection and the outcome of second bone marrow transplants (BMT). The number of patients experiencing graft rejection declined significantly over the study period from 32% to 8% (p < 0.0001). This coincided with the introduction of cyclosporine to the conditioning regimen for BMT. The graft rejection rate in the post-hepatitis SAA group was significantly lower than in the group with idiopathic SAA (4% vs 20%) (p = 0.001). The use of irradiation in the conditioning regimen significantly reduced the number of patients experiencing graft rejection (7% vs 21%) (p = 0.004). Age, sex and severity of disease did not influence the rate of sustained engraftment. Of the 85 patients experiencing graft rejection, 41 received a second transplant: their survival is 33% vs 8% for patients not transplanted a second time (p = 0.003). The major factor predicting the outcome of second BMT for SAA was the interval from first BMT. Patients receiving a second BMT within 60 days from the first BMT had a significantly poorer outcome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199566

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  26 in total

1.  Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.

Authors:  K Ishiyama; J Takeda; T Kondo; N Sugimoto; H Kawabata; T Kitano; A Takaori-Kondo
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

2.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

3.  Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis.

Authors:  H Alchalby; D-R Yunus; T Zabelina; F Ayuk; N Kröger
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

4.  Graft failure.

Authors:  Shaun McCann
Journal:  Bone Marrow Transplant       Date:  2020-03-11       Impact factor: 5.483

5.  Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.

Authors:  Chayamon Takpradit; Susan E Prockop; Nancy A Kernan; Andromachi Scaradavou; Kevin Curran; Julianne Ruggiero; Nicole Zakak; Richard J O'Reilly; Farid Boulad
Journal:  J Pediatr Hematol Oncol       Date:  2018-05       Impact factor: 1.289

6.  Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia.

Authors:  K Kudo; H Muramatsu; N Yoshida; R Kobayashi; H Yabe; K Tabuchi; K Kato; K Koh; Y Takahashi; Y Hashii; Y Kawano; M Inoue; Y Cho; H Sakamaki; K Kawa; K Kato; R Suzuki; S Kojima
Journal:  Bone Marrow Transplant       Date:  2015-06-29       Impact factor: 5.483

7.  Second unrelated donor hematopoietic cell transplantation for primary graft failure.

Authors:  Jeffrey Schriber; Manza-A Agovi; Vincent Ho; Karen K Ballen; Andrea Bacigalupo; Hillard M Lazarus; Christopher N Bredeson; Vikas Gupta; Richard T Maziarz; Gregory A Hale; Mark R Litzow; Brent Logan; Martin Bornhauser; Roger H Giller; Luis Isola; David I Marks; J Douglas Rizzo; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-19       Impact factor: 5.742

8.  Total lymphoid irradiation based conditioning for hematopoietic stem cell transplantation in severe aplastic anemia.

Authors:  Yun-Hee Lee; Ji-Yoon Kim; Byung-Ock Choi; Mi-Ryeong Ryu; Su-Mi Chung
Journal:  Radiat Oncol J       Date:  2012-12-31

9.  HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease.

Authors:  Marianne E McPherson; Alan R Anderson; Marta-Inés Castillejo; Christopher D Hillyer; Robert A Bray; Howard M Gebel; Cassandra D Josephson
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

10.  Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.

Authors:  Rajat Kumar; Fumihiko Kimura; Kwang Woo Ahn; Zhen-Huan Hu; Yachiyo Kuwatsuka; John P Klein; Marcelo Pasquini; Koichi Miyamura; Koji Kato; Ayami Yoshimi; Yoshihiro Inamoto; Tatsuo Ichinohe; William Allen Wood; Baldeep Wirk; Matthew Seftel; Philip Rowlings; David I Marks; Kirk R Schultz; Vikas Gupta; Laurence Dedeken; Biju George; Jean-Yves Cahn; Jeff Szer; Jong Wook Lee; Aloysius Y L Ho; Anders Fasth; Theresa Hahn; Nandita Khera; Jignesh Dalal; Carmem Bonfim; Mahmoud Aljurf; Yoshiko Atsuta; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-18       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.